SION · Sionna Therapeutics, Inc. · Debt
$3.60
-0.20 (-5.26%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. The Company believes that its existing cash, cash equivalents and marketable securities of $268.3 million as of June 30, 2026, will be sufficient to allow the Company to fund operations beyond twelve months from the date that the financial statements are issued.”View the 10-Q filed Aug 6, 2026
Market Cap
$162.76M
Shares
45.21M
Volume · Oct 23
918.2K
Avg daily vol (3M)
2.24M
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2026-06-30 | USD 1,377,000 | 10-Q filed 2026-08-06 |
| Noncurrent operating lease liabilities | 2026-06-30 | USD 6,692,000 | 10-Q filed 2026-08-06 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Key facts
CIK
2036042
CUSIP
829401108
13F (30d)
14 filings
14 filers
Visit website
Investor relations